Individualised versus conventional enoxaparin dosing: a randomised controlled trial

Phase 4

Completed

• Conditions: Acute Coronary Syndrome; Deep Vein Thrombosis; Atrial Fibrillation; Pulmonary Embolism; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12608000573358
• Lead Sponsor: School of Pharmacy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-11-12
• Study Completion: 2012-02-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

All patients admitted for treatment with enoxaparin who are likely to require treatment for at least 48 hours are eligible for inclusion into the study.

Exclusion Criteria

Patients who are pregnant; less than 18 years old; have received warfarin in the past 7 days or heparin therapy (unfractionated heparin 'UFH' or low-molecular weight heparin 'LMWH') in the last day; have an international normalised ratio 'INR' > 1.2 or an Activated Partial Thromboplastin Time 'APTT' > 60 seconds at the time of recruitment; or an estimated creatinine clearance less than 10 ml/min (using the Cockcroft and Gault equation calculated based on lean body weight).

Study & Design

• Study Type: Interventional
• Study Design: Not specified